

# Potential Histamine H<sub>2</sub>-Receptor Blockers. 3- and 2-Indole Derivatives as Immobile Analogues of Tautomeric Forms of Cimetidine

Haile Tecle,\* Lillian Robichaud, and Charles F. Schwender

Departments of Chemistry and Pharmacology, Warner-Lambert/Parke-Davis Pharmaceutical Research Division, Ann Arbor, Michigan 48106. Received December 1, 1980

At physiological pH, cimetidine (1a) and its analogues burimamide (1b) and metiamide (1c) exist mainly as an equilibrium mixture of tautomers. A high concentration of tautomer 2 is associated with increased H<sub>2</sub>-receptor interaction. 3-Indole derivatives (5c-f) and 2-indole derivatives (6c-f) were synthesized and tested as immobile analogues of tautomers 2 and 3, respectively. Weak competitive H<sub>2</sub> antagonism was found in *N*-cyano-*N*-[2-[(1*H*-indol-3-ylmethyl)thio]ethyl]carbamidothioic acid methyl ester (5e) and *N*-[2-[(1*H*-indol-2-ylmethyl)thio]ethyl]-*N*'-methylthiourea (6c).

At physiological pH, the potent H<sub>2</sub>-receptor blockers cimetidine (1a), thioburimamide (1b), and metiamide (1c) (Chart I) exist mainly as an equilibrium mixture of tautomers 2 and 3 (80-93%), with little formation of cation 4 (7-20%).<sup>1</sup> Increased concentration of tautomer 2 is associated with high H<sub>2</sub>-receptor interaction.<sup>1</sup>

In an attempt to generate immobile forms of tautomers 2 and 3, the synthesis and biological screening of compounds 5c-f and 6c-f were undertaken.

**Chemistry.** Treatment of quaternary salts 5a<sup>2</sup> and 6a<sup>3</sup> with excess 2-aminoethanethiol hydrochloride in the presence of base rendered amines 5b and 6b, respectively. These, in turn, were reacted with methyl and phenyl isothiocyanate to give the corresponding thioures 5c,d and 6c,d. Reaction of amines 5b and 6b with dimethyl cyanocarbonimidodithioate in dimethoxyethane resulted in intermediates 5e and 6e, which upon treatment with MeNH<sub>2</sub>-MeOH rendered compounds 5f and 6f.


## Biological Results and Discussion

The chronotropic response of guinea pig atria to histamine or other H<sub>2</sub> agonists is blocked by the competitive antagonist cimetidine and its analogues.<sup>4</sup>

A chronotropic H<sub>2</sub> antagonism test consists of exposing guinea pig atria to increasing doses of the H<sub>2</sub> agonist, 4-methylhistamine. A parallel shift of the dose-response curve to the right at concentrations of drug which have no effect on the resting heart rate serves as the criterion for competitive H<sub>2</sub> antagonisms.<sup>5-7</sup>

Compounds 5c-f and 6c-f were tested for this competitive H<sub>2</sub> antagonism. Activity is expressed as the "potency ratio", defined as the additional amount of agonist needed in the presence of antagonist to obtain the percent EC<sub>50</sub> maximum response (Table I). As defined, compounds 5e and 6c met the criterion for competitive H<sub>2</sub> antagonism, and compounds 5c,d,f did not shift the dose-response curve and were inactive. Compound 6d lowered resting rate and was toxic to the tissues. Compound 6e shifted the curve significantly but not in a parallel manner. The effect was not surmountable by additional agonist, 4-methylhistamine, a criterion for competitive antagonism.

Chart I



Additional experiments would be required to establish if the compound is a noncompetitive H<sub>2</sub> antagonist. Compound 6f caused variable base-line effects, increasing resting rate initially, then decreasing the rate.

Compounds 5c-f, as analogues of tautomer 2, were expected to show greater activity than 6c-f. This, however, was not the case. Compound 5e is weakly active. 6c is also a weak competitive H<sub>2</sub> antagonist, in contrast to its counterpart 5c which is inactive.

Recently synthesized histamine H<sub>2</sub> blockers in which the imidazole ring is replaced by thiazole<sup>8</sup> and furan rings<sup>9</sup> clearly demonstrated that imidazole tautomerism per se is not a determining molecular feature for antagonism. This does not, however, preclude the possibility that with imidazole derivatives activity may reside within a particular tautomer.

## Experimental Section

Melting points are uncorrected. The NMR spectra were obtained in CDCl<sub>3</sub> on a Varian EM 390 spectrometer. Chemical shifts are expressed in parts per million (ppm) on the scale from internal Me<sub>4</sub>Si. The IR spectra were measured on a Digilab Model FT 14 spectrometer. The spectroscopic data for all new com-

- C. R. Ganellin, in "Histamine Receptors, Proceeding of the A. N. Richards Symposium", Tobias O. Yellin, Ed., Spectrum Publications, Jamaica, New York, 1979, p 377 and references therein.
- T. A. Geissman and A. Armen, *J. Am. Chem. Soc.*, **74**, 3916 (1952).
- W. Schindler, *Helv. Chim. Acta.*, **40**, 2156 (1957).
- R. W. Brimblecombe, W. A. M. Duncan, G. J. Durant, C. R. Ganellin, M. E. Partons, and J. W. Black, *Br. J. Pharmacol.*, **53**, 435 (1975).
- R. B. Parker and D. R. Waud, *J. Pharmacol. Exp. Ther.*, **177**, 1 (1971).
- D. R. Waud, *Adv. Gen. Cell. Pharmacol.*, **1**, 145 (1975).
- T. Levy, *Methods Pharmacol.*, **1**, 77 (1971).

(8) T. O. Yellin, S. H. Buck, D. J. Gilman, D. F. Jones, and T. M. Wordleworth, *Life Sci.*, **25**, 2001 (1979).

(9) D. B. Judd, J. M. Clintherow, B. J. Price, and J. Bradshaw, European Patent 1-699 (1979).

Table I. Antagonism of 4-Methylhistamine Induced Guinea Pig Atria Chronotropic Response (Potency Ratio at  $3 \times 10^{-5}$  M)

5c-f					6c-f				
no.	R <sub>1</sub>	R <sub>2</sub>	potency ratio <sup>a</sup>	competitive antagonism <sup>b</sup>	no.	R <sub>1</sub>	R <sub>2</sub>	potency ratio <sup>a</sup>	competitive antagonism <sup>b</sup>
5c	S	NHCH <sub>3</sub>	1.06	- <sup>c</sup>	6c	S	NHCH <sub>3</sub>	3.35	+
5d	S	NHC <sub>6</sub> H <sub>5</sub>	1.16	- <sup>c</sup>	6d	S	NHC <sub>6</sub> H <sub>5</sub>	2.54	- <sup>e</sup>
5e	NCN	SCH <sub>3</sub>	2.56	+	6e	NCN	SCH <sub>3</sub>	6.04	- <sup>d</sup>
5f	NCN	NHCH <sub>3</sub>	0.84	- <sup>c</sup>	6f	NCN	NHCH <sub>3</sub>	1.76	- <sup>e</sup>
cimetidine (1d)			36.8	+	cimetidine (1d)			36	+

<sup>a</sup> Potency ratio = % EC<sub>50</sub> max of test compound/% EC<sub>50</sub> max of control. <sup>b</sup> Conditions for significant competitive antagonism (+) = (1) potency ratio > 1.0 ( $p < 0.05$ ), (2) parallel shift in dose-response curve with slopes not significantly different ( $p > 0.05$ ), and (3) no effect on resting heart rate. Failure to meet any of the above conditions leads to inactivity (-). <sup>c</sup> Potency ratio not significantly greater than 1.0 ( $p > 0.05$ ). <sup>d</sup> Nonparallel shift in dose-response curve; slope significantly different ( $p < 0.05$ ). <sup>e</sup> Effect on resting heart rate ( $p < 0.05$ ).

pounds were consistent with the assigned structures. Microanalytical results were within  $\pm 0.4\%$  of theory.

**2-[(1*H*-Indol-3-ylmethyl)thio]ethanamine (5b).** To an ice-cooled solution of 2-aminoethanethiol hydrochloride (9.0 g, 0.08 mol) in H<sub>2</sub>O (100 mL) containing sodium hydroxide (6.4 g, 0.16 mol) was added dropwise a solution of gramine methiodide<sup>2</sup> (9.48 g, 0.03 mol) in H<sub>2</sub>O (200 mL) with stirring. After 15 min of stirring at room temperature, the reaction mixture was extracted with Et<sub>2</sub>O, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to give 5b as an oil: yield 2.78 g (62%). This was used without further purification.

**N-[2-[(1*H*-Indol-3-ylmethyl)thio]ethyl]-*N*'-methylthiourea (5c).** To a solution of 5b (2.78 g, 0.014 mol) in Et<sub>2</sub>O (100 mL) was added dropwise a solution of methyl isothiocyanate (1.5 g, 0.02 mol) in Et<sub>2</sub>O (25 mL). A white precipitate resulted. Stirring was continued at room temperature for 30 min. The precipitate was separated by suction filtration and washed with Et<sub>2</sub>O to yield 2.22 g (59%) of 5c as a white solid, mp 98.5–99 °C. Anal. (C<sub>13</sub>H<sub>17</sub>N<sub>3</sub>S<sub>2</sub>) C, H, N, S.

**N-[2-[(1*H*-Indol-3-ylmethyl)thio]ethyl]-*N*'-phenylthiourea (5d).** To a solution of 5b (2.38 g, 0.012 mol) in Et<sub>2</sub>O (50 mL) was added dropwise a solution of phenyl isothiocyanate (1.55 g, 0.012 mol) in Et<sub>2</sub>O (25 mL) with stirring. After the solution was stirred at room temperature for 24 h, the resulting precipitate was separated and washed with a little Et<sub>2</sub>O to render 5d as a white solid: yield 3.10 g (78%); mp 154–155 °C. Anal. (C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>S<sub>2</sub>) H, N, S; C: calcd, 63.31; found, 62.82.

**Methyl *N*'-Cyano-*N*'-[2-[(1*H*-indol-3-ylmethyl)thio]ethyl]carbamimidodithioate (5e).** To a solution of 5b (2.06 g, 0.01 mol) in EtOH (10 mL) was gradually added a solution of dimethyl cyanocarbonimidodithioate (1.46 g, 0.01 mol) in EtOH (20 mL) with stirring. Stirring was continued for 16 h at room temperature. The reaction mixture was concentrated to give an oil, which upon trituration with Et<sub>2</sub>O gave 5e as a white solid: yield 3.02 g (99%); mp 132–135 °C. An analytical sample was obtained by recrystallization from EtOH, mp 137–138 °C. Anal. (C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>S<sub>2</sub>) C, H, N, S.

***N*'-Cyano-*N*'-[2-[(1*H*-indol-3-ylmethyl)thio]ethyl]-*N*'-methylguanidine (5f).** To a solution of 5e (2.19 g, 0.0072 mol) in MeOH (100 mL) was added dropwise an 18.6% solution of MeNH<sub>2</sub> in EtOH (24.2 mL, 0.144 mol) with stirring. After 18 h of stirring at room temperature, the reaction mixture was concentrated to give an oily residue. Trituration of the residue with ether gave crude 5f as white solid, mp 120–125 °C. Recrystallization from CH<sub>2</sub>Cl<sub>2</sub> raised the melting point to 130.5–131.5 °C: yield 1.72 g (84%). Anal. (C<sub>14</sub>H<sub>17</sub>N<sub>5</sub>S) H, N, S; C: calcd, 58.51; found, 57.90.

**2-[(1*H*-Indol-2-ylmethyl)thio]ethanamine (6b).** To a stirred, ice-cooled solution of MeONa (9.72 g, 0.18 mol) in MeOH (50 mL) was added dropwise a solution of 2-aminoethanethiol

hydrochloride (10.17 g, 0.09 mol) in MeOH (50 mL). The reaction mixture was allowed to stir at room temperature for 1 h. To this a solution of 6a<sup>3</sup> (9.49 g, 0.03 mol) in MeOH was added gradually with stirring. After stirring at room temperature for 3 h, the reaction mixture was refluxed for 16 h. While the mixture cooled to room temperature, a white precipitate settled down. This was filtered off, and the filtrate was concentrated to give an oil. The oil was suspended in H<sub>2</sub>O (80 mL) and stirred. A white solid precipitate separated. The solid was separated by suction filtration, dissolved in CHCl<sub>3</sub>, dried (NaSO<sub>4</sub>), and concentrated to give 6b as a white solid: yield 6.0 g (97%); mp 119.5–121 °C.

**N-[2-[(2*H*-indol-2-ylmethyl)thio]ethyl]-*N*'-methylthiourea (6c).** A solution of 6b (1.03 g, 0.05 mol) and methyl isothiocyanate (0.73 g, 0.01 mol) in dimethoxyethane (60 mL) was stirred at room temperature for 16 h. The solvent was removed and the oily residue was chromatographed on silica using CHCl<sub>3</sub> and CHCl<sub>3</sub>-EtOAc (1:1, v/v) as eluents to give 6c as a white solid: yield 1.01 g (72%); TLC *R*<sub>f</sub> 0.3 (silica; CHCl<sub>3</sub>-EtOAc, 1:1, v/v); mp 103–105 °C. Anal. (C<sub>13</sub>H<sub>17</sub>N<sub>3</sub>S<sub>2</sub>) C, H, N, S.

**N-[2-[(1*H*-indol-2-ylmethyl)thio]ethyl]-*N*'-phenylthiourea (6d).** This compound was prepared in similar manner to 6c from 6b (1.03 g, 0.003 mol) and phenyl isothiocyanate (1.35 g, 0.01 mol): yield 1.20 g (70%); TLC *R*<sub>f</sub> 0.63 (silica; CHCl<sub>3</sub>-EtOAc, 1:1, v/v); mp 141–142 °C. Anal. (C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>S<sub>2</sub>) C, H, N, S.

**Methyl *N*'-Cyano-*N*'-[2-[(1*H*-indol-2-ylmethyl)thio]ethyl]carbamimidodithioate (6e).** This compound was prepared as described for the preparation of 5e from 6b (2.06 g, 0.01 mol) and dimethyl cyanocarbonimidodithioate (11.46 g, 0.01 mol) with dimethoxyethane in place of EtOH as the solvent: yield 2.6 g (89%); mp 158–159 °C. Recrystallization from MeOH raised the melting point to 158.5–160 °C. Anal. (C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>S<sub>2</sub>) H, N, S; C: calcd, 58.23; found, 54.69.

***N*'-Cyano-*N*'-[2-[(1*H*-indol-2-ylmethyl)thio]ethyl]-*N*'-methylguanidine (6f).** This compound was prepared in similar manner as 5f from 6e (1.33 g, 0.0044 mol) and 70 mL of 31% MeNH<sub>2</sub> in MeOH. A suspension of the crude product in a minimum amount of MeOH was stirred for 10 min and filtered, and the filtrate was discarded. The white solid residue (6f) had a melting point of 158–158.5 °C: yield 0.81 g (65%). Anal. (C<sub>14</sub>H<sub>17</sub>N<sub>5</sub>S) H, N, S; C: calcd, 58.51; found, 58.00.

**Guinea Pig Atria Chronotropic Response.** Male guinea pigs, 350–600 g, were stunned by a blow to the head and killed by exsanguination. The heart was removed and placed in a modified Ringer-Locke buffer (pH 7.4) containing 0.003% atropine sulfate at  $37 \pm 2$  °C and gassed with 95% O<sub>2</sub>/5% CO<sub>2</sub>. The atria were dissected and suspended at 0.1–0.2 g resting tension in a tissue bath of the same gassed buffer. The bath temperature was maintained at  $37 \pm 2$  °C. Contractions were measured isometrically with a Grass (Model FT0.03C) force-displacement

transducer. Atrial heart rate (beats per minute, bpm) were recorded on a Beckman RM dyanograph recorder with Model 481B preamplifiers and Model 482M8 amplifiers.

Cumulative dose-response curves for the agonist, 4-methylhistamine, induced atrial rates before (curve I) and in the presence of (curve II) test compounds or cimetidine were generated as described below. After three washes of buffer 15 min apart, a control fast record (25 mm/s) was obtained to determine the atrial resting rate, followed by administration of the agonist. Resting rates varied from 180 to 200 bpm. After each agonist response peak, another fast record was obtained before the next dose of agonist. Maximum increases in heart rate were 150-180 bpm.

The agonist was given in cumulative doses of  $10^{-7}$ ,  $3 \times 10^{-7}$ ,  $10^{-6}$ ,  $3 \times 10^{-6}$ ,  $10^{-5}$ ,  $3 \times 10^{-5}$ , and  $10^{-4}$  M final bath concentrations. The rate of response of 4-methylhistamine peaked within 3 min and remained stable for a number of minutes thereafter. All fast records were taken within 4 min after administration of each dose of agonist.

Upon completion of the cumulative agonist responses, the tissue was washed repeatedly with changes of buffer 10 to 15 min apart until the atrial rate returned to control levels  $\pm 15$  bpm. Fifteen minutes after control atrial rates were reached, the test compound ( $3 \times 10^{-5}$  M) was added and the process repeated.

A nonlinear fit with a common maximum and slope to quan-

titative data was performed using program EDXXPH<sup>5,6</sup> (delta response). This analyzes the two curves simultaneously, estimates the potency ratio of the  $EC_{50}$  max value with SE, and calculates the parallelism variance ratio. The potency ratio has a 95% confidence region [ $\pm SE(t)$ ].

The potency ratio was derived by dividing the agonist  $EC_{50}$  max of curve II by the agonist  $EC_{50}$  max of curve I. The potency ratio reports how much more agonist was needed in the presence of the test compound to obtain the same heart rate response as with agonist alone.

Modified Ringer-Locke solution was prepared by dissolving 9.0 g of NaCl, 0.42 g of KCl, 1.0 g of  $NaHCO_3$ , 0.317 g of  $CaCl_2 \cdot 2H_2O$ , 0.005 g of  $MgCl_2 \cdot 6H_2O$ , 0.5 g of dextrose, and 0.3 mg of atropine sulfate in 1 L of triple distilled water. The pH was maintained at 7.4 by bubbling 95%  $O_2$ /5%  $CO_2$  (Matheson) constantly through the solution and adding acid or base as needed. The finished solution was placed in a reservoir which maintains a constant temperature of 37 °C. The buffer was made fresh each day.

**Acknowledgment.** We are grateful to S. England, E. Schoeb, R. B. Scott, C. Spurlock, and F. A. MacKellar for spectral data, C. E. Childs and his staff for the microanalyses, and K. Webster for biological assay.

## Antiinflammatory 5,6-Dihydro-11-oxodibenz[*b,e*]azepine-3-acetic Acids<sup>1</sup>


James P. Dunn, Joseph M. Muchowski, and Peter H. Nelson\*

Institute of Organic Chemistry, Syntex Research, Stanford Industrial Park, Palo Alto, California 94304.

Received March 2, 1981

A number of 5,6-dihydro-11-oxodibenz[*b,e*]azepine-3-acetic acids were synthesized. The compounds were up to ~30 times more potent than phenylbutazone as antiinflammatory agents. However, unlike some closely related compounds, for example, the isomeric 2-acetic acids, the compounds were almost devoid of activity in the mouse writhing analgesic assay.


In recent years, substantial antiinflammatory and analgesic activities have been reported for arylacetic and arylpropionic acids, in which the aryl group consisted of a tricyclic moiety with a seven-membered central ring. Thus, the 3-substituted dibenzotropones 1a,<sup>2</sup> the 2- and



- 1a, X-Y = CH=CH  
 b, X-Y = CH<sub>2</sub>O  
 c, X-Y = CH<sub>2</sub>S  
 d, X-Y = CH<sub>2</sub>N

3-substituted dibenzoxepins 1b,<sup>3,4</sup> and the 3-substituted dibenzothiepins 1c<sup>5</sup> have been subjected to advanced study as potential antiarthritic agents. The syntheses and bio-

Scheme I<sup>a</sup>



<sup>a</sup> Ts = *p*-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>.

logical activities of a number of acetic and propionic acids attached to the 2 position of 5,6-dihydro-11-oxodibenz[*b,e*]azepine (1d) have also been described.<sup>6</sup> We report here the preparation and bioassays of the isomeric 3-acetic and 3-propionic acids.

**Chemistry.** The compounds were synthesized as shown in Scheme I. Base-catalyzed alkylation of dimethyl 2-(*p*-toluenesulfonamido)terephthalate (2) with benzyl bromide or 3-methoxybenzyl bromide gave the products 3 (X = OCH<sub>3</sub>), which were converted to the acids by base hydrolysis. Attempted cyclization to the tricycle 4 using polyphosphoric acid was unsuccessful, but the derived acid chlorides (3, X = Cl) could be cyclized in the presence of

- (1) Contribution No. 565 from the Syntex Institute of Organic Chemistry.
- (2) Dunn, J. P.; Green, D. M.; Nelson, P. H.; Rooks, W. H.; Tomolonis, A.; Untch, K. G. *J. Med. Chem.* 1977, 20, 1557.
- (3) Lassman, H. B.; Kirby, R. E.; Wilker, J. C.; Novick, W. J. *Pharmacologist* 1975, 17, 226.
- (4) (a) Ueno, K.; Kubo, S.; Tagawa, H.; Yoshioka, T.; Tsukada, W.; Tsubokawa, M.; Kojima, H.; Kasahara, A. *J. Med. Chem.* 1976, 19, 941. (b) Tsukada, W.; Tsubokawa, M.; Masukawa, T.; Kojima, H.; Kasahara, A. *Arzneim.-Forsch.* 1978, 28, 128.
- (5) Ackrell, J.; Antonio, Y.; Franco, F.; Landeros, R.; Leon, A.; Muchowski, J. M.; Maddox, M. L.; Nelson, P. H.; Rooks, W. H.; Roszkowski, A. P.; Wallach, M. B. *J. Med. Chem.* 1978, 21, 1035.